Aberdeen Standard Investments’ AIPUT fund (Airport Industrial Property Unit Trust) has secured a lease extension to 2030 with Kuehne+Nagel for its Heathrow South Cargo Centre warehouse at Heathrow Airport, securing the site’s pivotal role as a nationally-important facility for the movement and storage of imported/exported pharmaceuticals and other medical products, such as life science-related IT equipment. Heathrow South Cargo Centre is one of a number of AIPUT’s locations working to boost the nation’s resilience in the fight against Covid-19.
Kuehne+Nagel - the world’s second largest airfreight forwarder - is an established customer of AIPUT, having operated out of the 208,000 sq ft Heathrow South Cargo Centre since 2014. GlaxoSmithKline is a leading customer of the warehouse facility, which represents a significant share of the UK’s pharmaceutical imports and exports. Kuehne+Nagel is joined at the Heathrow South Cargo centre by Do&Co Catering and GE Aviation.
Heathrow Airport is the largest UK import hub for pharmaceuticals and medical products, handling up to 41% by value of the UK’s total pharmaceutical imports. AIPUT has supported the business growth of Kuehne+Nagel’s specialist air-cargo divisions on a number of occasions in recent years. The company also operates AIPUT’s Perishables Handling Centre at Hatton Cross, a 72,500 sq on-airport temperature-controlled warehouse facility specifically designed to process imported food airfreight from all over the world.
Heathrow has been repurposed in recent weeks to focus mainly on importing essential airfreight products to feed and support the UK’s recovery. The gateway airport is currently handling up to 95 dedicated cargo flights each day - 14 times the number in normal times. Overall cargo volumes passing through the airport have been significantly lower than usual due to the dramatic reduction in belly-freight usually carried in long-haul passenger aircraft.
Nick Smith, Fund Manager for AIPUT said: “Kuehne+Nagel is one of a number of AIPUT customers and commercial partners at Heathrow that have responded magnificently in ramping up their business operations to help support the nation’s health - in particular our NHS - in the most challenging circumstances. It’s hugely inspiring to see businesses vital to the operations of our leading airports, stepping up to the mark and proving the importance of the UK’s aviation industry to our national wellbeing, as well as to the future economic recovery of UK plc.
“This new agreement with our valued partners Kuehne+Nagel, secures the future of this nationally-important air freight facility for years to come, making a major contribution towards ensuring that the UK’s vital access to global healthcare supplies is maintained.”
AIPUT is supporting its customers across the portfolio and through their warehouse facilities to actively support the UK through the Covid-19 emergency:
AIPUT manages over 2.1m sq ft of high-quality cargo warehousing serving Heathrow Airport, making the fund one of the airport’s leading specialist real estate landlords. Resolution to grant planning permission has recently been secured for two new warehouse buildings set to deliver a further 145,000 sq ft of airport-related warehousing serving Heathrow, divided between its dnata City East campus, South Heathrow, and Blackthorne Point site, west of Heathrow which will contribute to the economic and social recovery of both the local area and wider UK.
-Ends-
For further images or information, please contact:
Melissa Carver/John Mills: 020 7630 1411
AIPUT@thecommunicationgroup.co.uk
The Communication Group plc
Notes to Editors:
About AIPUT
About Aberdeen Standard Investments
Important Information
For Professional Investors only
The value of investments, and the income from them, can go down as well as up and you may get back less than the amount invested. Past performance is not a guide to future results. Tax treatment depends on the individual circumstances of each investor and may be subject to change in the future. We recommend that you seek financial advice prior to making an investment decision.
The details contained here are for information purposes only and should not be considered as an offer, investment recommendation, or solicitation to deal in any investments or funds and does not constitute investment research, investment recommendation or investment advice in any jurisdiction. Any research or analysis used to derive, or in relation to, the above information has been procured by us for our own use, without taking into account the investment objectives, financial situation or particular needs of any specific investor, and may have been acted on for own purpose. No warranty is given as to the accuracy, adequacy or completeness of the information contained in this communication and no liability for errors or omissions in such information. Readers must make assessments to the relevance, accuracy and adequacies of the information contained in this communication and make independent investigations, as they may consider necessary or appropriate for the purpose of such assessments. Any opinion or estimate contained in this communication, are made on a general basis. No information contained herein constitutes investment, tax, legal or any other advice, or an invitation to apply for securities in any jurisdiction where such an offer or invitation is unlawful, or in which the person making such an offer is not qualified to do so.
Issued in the United Kingdom (UK) by Aberdeen Asset Managers Limited, registered in Scotland (SC108419) at 10 Queen’s Terrace, Aberdeen, AB10 1XL, and Standard Life Investments Limited registered in Scotland (SC123321) at 1 George Street, Edinburgh EH2 2LL. Both companies are authorised and regulated in the UK by the Financial Conduct Authority.